Objective: This study was designed to investigate the effect of angiotensin (17), a Mas receptor agonist, and A-779, a Mas receptor antagonist, in rats with diabetic cardiomyopathy (DC). Methods: Rats treated with a single injection of streptozotocin (50 mg/kg, intraperitoneal), developed DC after 8 weeks. The extent of DC was assessed by measuring the left ventricular weight/body weight (LVW/BW) ratio, absolute LVW, left ventricular developed pressure (LVDP), maximum change in left ventricular pressure over time (dp/dt max ), minimum change in left ventricular pressure over time (dp/dt min ) , left ventricular (LV) protein content, LV collagen content, lipid profile, and serum nitrite/nitrate concentration. Test drug treatment was given from week 4 to week 8. Results: Angiotensin (17) treatment attenuated DC by significantly increasing LVDP, dp/dt max , dp/dt min , serum nitrite/nitrate concentration and significantly decreasing the LVW/BW ratio and LV collagen content. For the first time, this study has documented that endogenous angiotensin (17) regulates lipid profile in rats, and that treatment with angiotensin (17) significantly attenuates diabetes-induced changes in lipid profile. However, LV protein content and absolute LVW remain unaffected after treatment. Conclusion: Angiotensin (17) significantly attenuates DC in rats because of vasodilatory, antiproliferative and anifibrotic properties but also because of a significant decrease in dyslipidemia, the major culprit for cardiac dysfunctions in diabetes.
Introduction
Diabetes is a major public health problem in both developing and developed countries, which often leads to nephropathy, neuropathy, retinopathy, vasculopathy and cardiomyopathy [Brownlee, 2005] . Diabetic cardiomyopathy (DC) is a clinical condition characterized by left ventricular hypertrophy, cardiac dysfunction, alteration in coronary microcirculation, dyslipidemia and myocardial fibrosis [Poornima et al. 2006; Wang et al. 2006; Finck et al. 2003; Devereux et al. 2000 ].
The reninangiotensinaldoserone system (RAAS) is activated in diabetes mellitus [Miller et al. 1996] . Furthermore, increased formation of angiotensin II (Ang II) in diabetic rats has been related to hypertrophy of cardiomyocytes [Sajad et al. 2004 ]. The AT 1 receptor antagonist, losartan, has been noted to improve cardiovascular complications in diabetes [Brenner et al. 2001] , while irbesartan, has been shown to attenuate cardiac inflammation and cardiac fibrosis in streptozotocin (STZ)-induced DC [Dirk et al. 2007] .
Angiotensin converting enzyme-2 (ACE-2) is a new member of the RAAS [Donoghue et al. 2000; Tipnis et al. 2000 ]. ACE-2 expression has been noted in heart, kidneys, pancreas, brain, lungs and intestine [Crackower et al. 2002; Harmer et al. 2002] . ACE-2 is a zincmetalloproteinase, which hydrolyses Ang I and Ang II into Ang (19) and Ang (17) fragments respectively [Donoghue et al. 2000] . Ang (19) , in turn, is converted into Ang (17) by the enzymes known as neutral endopeptidase, polyendopeptidase and ACE [Vickers et al. 2002; Welches et al. 1993] . Ang (17) produces vasodilation, antifibrotic and antiproliferative effects through activation of specific Mas receptors [Ferreira and Santos, 2005; Santos et al. 2003; Giani et al. 2010 ]. Furthermore, genetic depletion of Mas receptors resulted in impaired cardiac function [Castro et al. 2006 ]. Transgenic ACE-2 knockout mice (ace2 / ) have been reported to suffer from severe cardiac dysfunction [Crackower et al. 2002] . However, in another study, ace2 / mice showed normal myocardial functions [Gurley et al. 2006 ]. ACE-2 mRNA and protein expression are significantly reduced in STZ-induced diabetic rats [Ye et al. 2004; Tikellis et al. 2003 ]. Our group recently reported that chronic administration of Ang (17) produced renoprotective effects by decreasing lipid deposits, ameliorating the changes in fatty acid composition in the renal cortex of diabetic rats [Singh et al. 2010a [Singh et al. , 2010b . Thus, the ACE-2Ang-(17)Mas axis may be involved in the development of DC.
The present study was designed to investigate the beneficial effect, if any, of Ang (17), a Mas receptor agonist, and its blockade by A-779, a Mas receptor antagonist, in STZ-induced DC.
Materials and methods
The experimental protocol used in this study was approved by the Institutional Animal Ethical Committee. Age-matched young Wistar rats, weighing about 200250g, were used. Rats were fed on standard chow diet and water ad libitum. They were acclimatized in an animal house and were exposed to a normal cycle of light and darkness.
Induction of experimental diabetic cardiomyopathy
Diabetes was induced by a single injection of STZ (50 mg/kg, intraperitoneal) dissolved in freshly prepared ice cold citrate buffer (pH 4.5). After 1 week of administration animals having a random serum glucose of more than 240 mg/dl were considered diabetic. DC develops 8 weeks after STZ administration, as reported earlier [Hamblin et al. 2007 ].
Experimental protocol
Seven groups were employed in the present study and each group comprised six to nine rats of either sex. Ang (17) and A-779 were dissolved in normal saline (0.9% weight/volume). Group 1 (normal control): rats were maintained on a standard food and water regime and no treatment was given. Group II [Ang (17) alone]: rats were administered Ang (17) (576 mg/kg/day, intraperitoneal) [Benter et al. 2007 ] from the fifth to the eighth week. Group III (A-779 alone): rats were administered A-779 (744 mg/ kg/day, intraperitoneal) [Al-Maghrebi et al. 2009 ] from the fifth to the eighth week. Group IV (diabetic control): rats were administered STZ (50 mg/kg, intraperitoneal, once) dissolved in citrate buffer (pH 4.5). Group V [Ang (17)treated diabetic group]: rats were treated with Ang (17) (576 mg/kg/day, intraperitoneal, 4 weeks), 4 weeks following STZ administration. Group VI (A-779-treated diabetic group): rats were treated with A-779 (744 mg/kg/day, intraperitoneal, 4 weeks), 4 weeks following STZ administration. Group VII [A-779 + Ang (17)-treated diabetic group]: rats were treated with A-779 (744 mg/kg/day, intraperitoneal, 4 weeks) 30 min before treatment with Ang (17) (576 mg/kg/day, intraperitoneal, 4 weeks), 4 weeks following STZ administration.
Haemodynamic and morphological assessments
After 8 weeks, the rats were sacrificed by spinal dislocation, the thorax was opened and the heart was excised after intraperitonial heparinization (500 U/kg body weight) and placed into chilled, heparinized perfusate to arrest the beating of the heart. The heart was immediately mounted on digital Langendorff's apparatus (RADNOTI, Monrovia, California, USA) and perfused with Kreb's Henseleit solution (NaCl 118 mM; KCl 4.7 mM; CaCl 2 2.5 mM; MgSO 4 .7H 2 O 1.2 mM; NaHCO 3 25 mM; KH 2 PO 4 1.2 mM; C 6 H 12 O 6 11 mM), gassed with 95% O 2 5% CO 2 , pH 7.4, maintained at 37 C. For the measurement of cardiac functions, a double distilled water-filled latex balloon was inserted through the mitral valve into the left ventricle and left ventricular developed pressure (LVDP, mmHg), maximum change in left ventricular pressure over time (dp/dt max , mmHg/s) and minimum change in left ventricular pressure over time (dp/dt min , mmHg/s) were measured using a pressure transducer (BIOPAC MP100 System, BIOPAC systems, Inc., Camino-Santa Barbara, California, USA). The left ventricle including interventricular septum weight was noted and expressed as milligram per gram of body weight.
Biochemical assessments
The following assessments were made.
Assessment of serum glucose and lipid profile. At the end of the experimental protocol, the venous blood samples were collected from the Therapeutic Advances in Cardiovascular Disease 5 (3) retro orbital sinus under light ether anaesthesia and serum was separated. The serum samples were frozen (at 20 C) until the biochemical parameters were analyzed. The serum glucose concentration was estimated by the glucose oxidase-peroxidase (GOD-POD) method [Trinder, 1969] , serum total cholesterol was estimated by the cholesterol oxidase-peroxidase (CHOD-POD) method [Allain et al. 1974] , serum triglyceride was estimated by the glycerophosphate oxidase-peroxidase (GPO-PAP) method [Trinder, 1969] and serum high-density lipoprotein (HDL) was estimated by the CHOD-POD method [Allain et al. 1974] using the commercially available kits (Coral Clinical System, Goa, India).
Total tissue lipids were extracted and washed with Folch wash reagent [Deepa and Varalakshmi, 2005; Folch et al. 1957] . For determination of left ventricular (LV) triglycerides and LV cholesterol, dried total lipid extract was dissolved in peroxide-free dioxane/isopropanol [Cho, 1983] and aliquots were taken for estimation using the commercially available kit (Coral Clinical System) according to earlier described methods, that is, the GPO-PAP method and the CHOD-POD method respectively.
Estimation
of serum nitrite/nitrate concentration. To determine total nitrite and nitrate, acidic Griess reaction for colour development after the reduction of nitrate with copper cadmium alloy was used [Sastry et al. 2002] .
Estimation of LV protein content and LV collagen content. The LV was stored at 20 C in liquid nitrogen for quantitative estimation of biochemical parameters. The LV protein content was determined spectrophotometrically at 750 nm by Lowry's method [Lowry et al. 1951 ]. The LV collagen content was estimated by measuring hydroxyproline concentration as described earlier [Jamall et al. 1981 ].
Statistical analysis
All values were expressed as mean±standard deviation. The data obtained from various groups were statistically analyzed using a oneway analysis of variance followed by Tukey's multiple range test. A p value < 0.05 was considered to be statistically significant.
Drugs and chemicals STZ was obtained from Sigma Aldrich Ltd (St Louis, Missouri, USA). Ang (17) peptide and A-779 were obtained from BACHEM, Bubendorf Switzerland. All other chemicals used in the present study were of analytical grade.
Results
The results obtained in various groups of experiments were as follows.
Effect of various pharmacological interventions in normal rats
The administration of Ang (17) alone to normal rats did not produce any significant effect on various parameters assessed in the present study. However, administration of A-779 to normal rats significantly increased total LV collagen content, LVW/BW ratio, serum triglycerides and LV triglycerides while significantly decreasing the LVDP, dp/dt max , dp/dt min , and serum nitrite/nitrate levels (see Tables 1 and 2 
, and Figures 13)
Effect of various pharmacological interventions on haemodynamic parameters in diabetic rats A significant decrease in LVDP, dp/dt max and dp/ dt min was noted in diabetic control rats. Treatment with Ang (17) significantly increased LVDP, dp/dt max and dp/dt min. Furthermore, treatment with concurrent administration of Ang (17) in the presence of A-779 in diabetic rats significantly decreased LVDP, dp/dt max and dp/dt min compared with the Ang (17) Effect of various pharmacological interventions on serum glucose and serum nitrite/nitrate levels in diabetic rats A significant increase in serum concentration of glucose was noted in diabetic rats. Treatment with Ang (17) and concurrent administration of Ang (17) in the presence of A-779 did not significantly affect the serum glucose concentration in diabetic rats. Furthermore, the serum concentration of nitrite/nitrate was decreased significantly in diabetic control rats. Treatment with Ang (17) significantly attenuated the decrease in serum nitrite/nitrate concentration. Pretreatment with A-779 nonsignificantly attenuated the Ang (17)-induced increase in serum nitrite/nitrate concentration in diabetic rats. (Table 1) .
Effect of various pharmacological interventions on LV protein content, LV collagen content, absolute LVW and LVW/BW ratio in diabetic rats A significant increase in LV protein content and LV collagen content was noted in diabetic control rats. Treatment with Ang (17) significantly decreased LV collagen content. Furthermore, administration of Ang (17) in the presence of A-779 significantly affected LV collagen content compared with Ang (17) alone treated diabetic rats.
A significant decrease in body weight was observed in STZ-treated rats. Treatment with Ang (17) significantly prevented the fall in body weight in diabetic rats. In diabetic rats, the decrease in absolute LVW (23.6±10.3%) was significantly less than the decrease in body weight (45±3.8%). In addition, a significant increase in LVW/BW ratio was noted in diabetic control rats. Treatment with Ang (17) alone significantly decreased LVW/BW ratio in diabetic rats. Pretreatment with A-779 significantly blocked the effect of Ang (17) on body weight and LVW/BW in diabetic rats ( Table 1) .
Effect of various pharmacological interventions on lipid profile in diabetic rats
Significant increases in serum triglycerides, total LV cholesterol and total LV triglycerides were Therapeutic Advances in Cardiovascular Disease 5 (3) noted in diabetic control rats. No significant change in serum cholesterol and serum HDL level was observed. Treatment with Ang (17) significantly reduced serum triglycerides, total LV cholesterol and total LV triglycerides and significantly increased serum HDL levels. Furthermore, the administration of A-779 in diabetic rats produced an additional nonsignificant increase in serum triglyceride levels compared with diabetic controls. Pretreatment with A-779 significantly attenuated the Ang (17)-induced increase in HDL levels and decrease in serum triglycerides, total LV cholesterol and total LV triglycerides in diabetic rats (Table 2) .
Discussion
The principal findings of this study are that treatment with Ang (17) significantly attenuates STZ-induced DC in Wister rats as evidenced by an increase in LVDP, dp/dt mas and dp/dt min . Decreases in LVDP, dp/dt max , and dp/dt min demonstrate abnormal LV systolic and diastolic function (increased ventricular stiffness) that is characteristic of DC [Hamblin et al. 2007 ]. Furthermore, Ang (17) (17), angiotensin (17); dp/dt max , maximum change in left ventricular pressure over time; DR, diabetic rats; NR, normal rats. a: p < 0.05 versus normal control; b: p < 0.05 versus diabetic control; c: p < 0.05 versus Ang (17) alone treated diabetic rats. [Singh et al. 2010b ]. Ang (17) also reduced LV hypertrophy, cardiac fibrosis and improved endothelial functions in diabetic rats.
It has been reported that Ang (17) improves the postischemic contractile function in isolated perfused rat hearts [Ferreira et al. 2002] and produces a significant increase in cardiac output and stoke volume in anaesthetized rats [Benter et al. 2006 ]. Crackower and colleagues [Crackower et al. 2002] noted severe cardiac dysfunction in ACE-2 knockout mice. However, Gurley and colleagues [Gurley et al. 2006] could not confirm this in their study in conscious ace2 / mice. In the present study, A-779, a specific Mas receptor antagonist, significantly decreased dp/dt min , dp/dt max , and serum nitrite/ nitrate concentration, and significantly increased LV collagen content, LVW/BW ratio, serum triglycerides, and total LV triglycerides in the normal rat, indicating that endogenous Ang (17) plays a physiological role in maintenance of normal cardiac function. Our results support the hypothesis of Crackower and colleagues [Crackower et al. 2002] .
Lipotoxicity has been reported to play an independent role in the pathogenesis of DC [Finck et al. 2003 ]. The diabetic heart uses more fat than glucose as a source of energy, resulting in increased levels of circulating fatty acids [Herrero et al. 2006 ]. If fatty acid oxidation fails to keep up with uptake, lipids can accumulate, producing lipotoxicity [Chiu et al. 2005; Cheng et al. 2004 ]. Furthermore, accumulation of triglyceride in the heart leads to impairment of myocardial function in diabetic mice [Nielsen et al. 2002] . Lipid deposition may directly impede cardiac metabolism and contractility or promote cardiomyocyte apoptosis [Chiu et al. 2005] . In our study too, the increase in LV lipid levels was associated with a significant change in LV haemodynamics, for example, a decrease in LVDP, dp/dt max , and dp/dt /min .
In our study in diabetic rats, the significant increase in serum triglyceride levels was associated with a significant increase in LV triglyceride levels. Similarly, a significant decrease in serum triglyceride levels on treatment with Ang (17) was associated with a significant decrease in LV triglyceride levels. Thus, an increase in tissue lipid levels can be explained by changes in lipid blood levels.
It has been reported that treatment with an ACE inhibitor (captopril) decreases free fatty acids in mice fed a high-fat diet [Weisinger et al. 2009 ], while lisinopril, another ACE inhibitor, produced a dose-dependent lipid-lowering effect in patients [Ruggenenti et al. 2003 ]. Furthermore, genetic depletion of ACE / has been shown to increase the expression of lipolytic enzymes in experimental animals, with altered metabolism of fatty acids in the liver [Jayasooria et al. 2008 ]. It has also been reported that the beneficial effects of ACE inhibitors and Ang receptor blockers may be due to activation of the Ang (17)/Mas-receptor axis [Ferrario et al. 2005a [Ferrario et al. , 2005b ]. An increase in Ang II levels and a decrease in expression of ACE-2 mRNA protein and activity have been reported in STZ-treated diabetic rats [Leehey et al. 2008; Singh et al. 2005] . Recently, we have reported that treatment with Ang (17) significantly decreases lipid deposits and ameliorates the changes in fatty acid composition in the renal cortex of STZ-treated rats. [Singh et al. 2010a [Singh et al. , 2010b . Because ACE-2 mediates the conversion of Ang II to Ang (17), the dyslipidemia observed in our study may be caused by decreased formation of endogenous Ang (17) and increased formation of endogenous Ang II. Thus, the beneficial effects of Ang (17) on lipid profile in diabetic rats, as well as in normal rats, suggests an active role of the ACE-2Ang-(17)Mas receptor axis in maintenance of a normal lipid profile. Moreover, even the beneficial effects of ACE inhibitors on lipid composition may be due to an increase in Ang (17) levels.
Exogenous administration of Ang (17) or AVE0991 (Mas receptor agonist) shows antifibrotic and antiprolifirative effects in cardiac tissue [Ferreira and Santos, 2005; Iwata et al. 2005 ]. In the diabetic rat, the decrease in LVW (23.6±10.3%) was significantly less than the decrease in body weight (45±3.8%). This provides indirect evidence that the increase in LVW/ BW ratio may be at least partially because of LV hypertrophy. Our results are in agreement with previous findings. Treatment with Ang (17) has been shown to decrease the LVW/BW ratio, and the LV collagen content justified antifibrotic and antiprolifirative effects of the peptide.
Vascular endothelial dysfunction is reported to be a major contributor to the development of DC [Ruggenenti et al. 2003 ]. It has been previously documented that Ang (17) increases nitric oxide release [Ferreira and Santos, 2005] . In support of our previous findings [Singh et al. 2010a [Singh et al. , 2010b , we observed that administration of Ang (17) to diabetic rats increased the nitrite/nitrate levels, which was significantly blocked in A-779 pretreated rats. Hence, it may be concluded that Ang (17), by improvement in nitric oxide levels, ameliorates cardiovascular dysfunction in diabetic rats.
The molecular mechanism of the cardioprotective effects of Ang (17) in diabetic rats is not fully understood. It may be because of stimulation of nitric oxide production [Sampaio et al. 2007 ], phosphorylation of Janus kinase 2 (JAK2), Insulin receptor substrate-1 (IRS-1) and Serine/threonine protein kinase (Akt) [Giani et al. 2007 ], inhibition of tumour necrosis factor a, nuclear factor kB activity and suppressed expression of inflammatory genes [Al-Maghrebi et al. 2009] , and attenuation of dyslipidemia as documented in our study.
On the basis of the above findings we can conclude that endogenous Ang (17) plays a physiological role in the maintenance of a normal lipid profile in the rat. In addition, treatment with Ang (17) significantly attenuates DC in rats, not only because of its vasodilatory, anifibrotic and antiproliferative properties, but also because of a significant decrease in dyslipidemia, which is a major cause of cardiac dysfunction in diabetes. This observation provides an additional mechanism that might be involved in the cardioprotective effects of Ang (17) in the diabetic rat heart.
Clinical implication
Because LV hypertrophy and dyslipidemia are independent risk factors, amelioration by Ang (17) 
